Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04315-8
Benralizumab (an anti-IL-5 receptor α antibody), compared to placebo, significantly reduced the risk of first flare in patients with hypereosinophilic syndrome.
Science News
